ACADIA PHARMACEUTICALS INC (ACAD) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001070494 · SEC filings checked Oct 17, 2026

    Next report
    Nov 3, 2026
    Estimated from reporting history (91-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $19.71
    Polygon.io daily close, Oct 15, 2026. End of day, not live.
    Trailing diluted EPS
    $2.23
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 8.8

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 4, 2026$308.0M$31.5M$0.18Filing
    Mar 31, 2026May 6, 2026$268.1M$3.6M$0.02Filing
    Dec 31, 2025Jan 13, 2026$284.0M$273.6M$1.61Filing
    Sep 30, 2025Nov 5, 2025$278.6M$71.8M$0.42Filing
    Jun 30, 2025Aug 6, 2025$264.6M$26.7M$0.16Filing
    Mar 31, 2025May 7, 2025$244.3M$19.0M$0.11Filing
    Dec 31, 2024Feb 26, 2025$259.6M$143.3M$0.86Filing
    Sep 30, 2024Nov 6, 2024$250.4M$32.8M$0.20Filing

    What would ACADIA PHARMACEUTICALS INC have to report for its valuation to change?

    At $19.71, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -5.5% a year, to $1.68. On that path the next quarter needs diluted EPS near $0.40, against $0.42 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year-5.5%-5.5%
    EPS needed in final year$1.68$1.68

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ACAD goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.